Nemus Bioscience Inc (NMUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nemus Bioscience Inc (NMUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH2340895D
  • |
  • Pages: 56
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Nemus Bioscience Inc (Nemus Bioscience) is a life-science and biopharmaceutical company that offers discovering, developing and commercializing cannabinoid-based therapeutics. The company's drug pipeline products include NB1111, NB1222, NB2111, NB2222 and Cannabinoid platform NB3111. Its cannabinoids comprise tetrahydrocannabinoal, cannabidiol, cannabinol, cannabichromene, cannbigerol and beta-caryophyllene, among others. Nemus Bioscience develops new chemical entities from a class of chemically diverse compounds called cannabinoids that molecules display pleiotropic activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. The company also develops novel and proprietary classes of product candidates that improve therapeutic options through enhanced chemical engineering and allow drug candidates to predictable bioavailability and pharmacokinetics. Nemus Bioscience is headquartered in Costa Mesa, California, the US.

Nemus Bioscience Inc (NMUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nemus Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Nemus Bioscience Raises USD2.4 Million in Venture Financing 12

Nemus Bioscience Secures USD0.62 Million in Venture Funding from Tylt Lab 13

Partnerships 14

Nemus Bioscience Enters into Agreement with Albany Molecular 14

Nemus Bioscience Enters into Development Agreement with Nanomerics 15

NEMUS Bioscience Enters into Agreement with Catalent Pharma Solutions 16

Nemus Bioscience Enters into Agreement with Albany Molecular Research 17

Nemus Bioscience Enters into Research Agreement with University of Mississippi for CIPN 18

University of Mississippi and Nemus Enter into Research Agreement For Glaucoma Treatment 19

University of Mississippi and Nemus Enter into Research Agreement For CBD Formulations 20

Nemus Bioscience Enters into Research Agreement with University of Mississippi 21

Nemus Enters into Research Agreement with University of Mississippi for MRSA 22

Nemus Bioscience Enters into Research Agreement with University of Mississippi 23

Licensing Agreements 24

Nemus Bioscience Enters into Licensing Agreement University of Mississippi 24

Nemus Bioscience Enters into Licensing Agreement with Teewinot Life Sciences 25

Nemus Bioscience Enters into Licensing Agreement with University of Mississippi for UM 8930 26

Nemus Bioscience Renews its Option Agreement with University of Mississippi 27

Nemus Enters into Licensing Agreement with University of Mississippi for UM 1490, UM 5070 and UM 8790 28

Equity Offering 29

NEMUS Bioscience Raises USD1.75 Million in Private Placement of Shares 29

Nemus Bioscience to Raise Funds through Public Offering of Shares 30

Nemus Bioscience Raises USD2 Million in Private Placement of Series F Preferred Stock 31

Nemus Bioscience Raises USD2 Million in Private Placement of Series F Preferred Stock 32

Nemus Bioscience to Raise USD20 Million in Private Placement of Series E Preferred Stock 33

Nemus Bioscience Announces to Raise Funds through Public Offering of Shares 34

Nemus Bioscience Plans to Raise Funds through Public Offering of Shares 35

NEMUS Bioscience Raises USD1.2 Million in Private Placement of Preferred Stock 36

Nemus Bioscience Raises USD0.7 Million in Second Tranche of Private Placement of Series D Preferred Stock 37

Nemus Bioscience Raises USD0.5 Million in First Tranche of Private Placement of Series D Preferred Stock 38

Nemus Bioscience Raises USD0.5 Million in Private Placement of Preferred Stock Financing 39

Nemus Bioscience Raises USD5 Million in Private Placement of Series B Convertible Preferred Stock 40

Nemus Bioscience Raises USD1.5 Million in Private Placement of Series A Preferred Stock 42

Nemus Raises USD0.38 Million in Private Placement of Series A Preferred Shares 43

Nemus Bioscience Raises USD0.3 Million in Private Placement of Series A Preferred Shares 44

Nemus Bioscience Raises USD0.7 Million in Private Placement of Shares 45

Nemus Bioscience Inc-Key Competitors 46

Nemus Bioscience Inc-Key Employees 47

Nemus Bioscience Inc-Locations And Subsidiaries 48

Head Office 48

Recent Developments 49

Corporate Communications 49

May 07, 2018: Nemus Bioscience Adds to Senior Leadership Team 49

Product News 50

11/06/2017: NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) at Upcoming Scientific Meetings 50

11/06/2017: NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Ocular Diseases (NB2222) at Upcoming Scientific Meetings 51

08/07/2017: NEMUS Bioscience Announces Presentation of CBD-analogue (NB2222) Ocular Data at the AAPS 2017 Annual Meeting 52

08/02/2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference 53

07/17/2017: Nemus Bioscience Announces NB2111 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting 54

06/22/2017: Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56

List of Figures

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nemus Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nemus Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nemus Bioscience Raises USD2.4 Million in Venture Financing 12

Nemus Bioscience Secures USD0.62 Million in Venture Funding from Tylt Lab 13

Nemus Bioscience Enters into Agreement with Albany Molecular 14

Nemus Bioscience Enters into Development Agreement with Nanomerics 15

NEMUS Bioscience Enters into Agreement with Catalent Pharma Solutions 16

Nemus Bioscience Enters into Agreement with Albany Molecular Research 17

Nemus Bioscience Enters into Research Agreement with University of Mississippi for CIPN 18

University of Mississippi and Nemus Enter into Research Agreement For Glaucoma Treatment 19

University of Mississippi and Nemus Enter into Research Agreement For CBD Formulations 20

Nemus Bioscience Enters into Research Agreement with University of Mississippi 21

Nemus Enters into Research Agreement with University of Mississippi for MRSA 22

Nemus Bioscience Enters into Research Agreement with University of Mississippi 23

Nemus Bioscience Enters into Licensing Agreement University of Mississippi 24

Nemus Bioscience Enters into Licensing Agreement with Teewinot Life Sciences 25

Nemus Bioscience Enters into Licensing Agreement with University of Mississippi for UM 8930 26

Nemus Bioscience Renews its Option Agreement with University of Mississippi 27

Nemus Enters into Licensing Agreement with University of Mississippi for UM 1490, UM 5070 and UM 8790 28

NEMUS Bioscience Raises USD1.75 Million in Private Placement of Shares 29

Nemus Bioscience to Raise Funds through Public Offering of Shares 30

Nemus Bioscience Raises USD2 Million in Private Placement of Series F Preferred Stock 31

Nemus Bioscience Raises USD2 Million in Private Placement of Series F Preferred Stock 32

Nemus Bioscience to Raise USD20 Million in Private Placement of Series E Preferred Stock 33

Nemus Bioscience Announces to Raise Funds through Public Offering of Shares 34

Nemus Bioscience Plans to Raise Funds through Public Offering of Shares 35

NEMUS Bioscience Raises USD1.2 Million in Private Placement of Preferred Stock 36

Nemus Bioscience Raises USD0.7 Million in Second Tranche of Private Placement of Series D Preferred Stock 37

Nemus Bioscience Raises USD0.5 Million in First Tranche of Private Placement of Series D Preferred Stock 38

Nemus Bioscience Raises USD0.5 Million in Private Placement of Preferred Stock Financing 39

Nemus Bioscience Raises USD5 Million in Private Placement of Series B Convertible Preferred Stock 40

Nemus Bioscience Raises USD1.5 Million in Private Placement of Series A Preferred Stock 42

Nemus Raises USD0.38 Million in Private Placement of Series A Preferred Shares 43

Nemus Bioscience Raises USD0.3 Million in Private Placement of Series A Preferred Shares 44

Nemus Bioscience Raises USD0.7 Million in Private Placement of Shares 45

Nemus Bioscience Inc, Key Competitors 46

Nemus Bioscience Inc, Key Employees 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Nemus Bioscience Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17848
Site License
USD 500 INR 35695
Corporate User License
USD 750 INR 53543

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com